This American Academy of Ophthalmology initiative provides ophthalmologists with a focused update on the latest data surrounding long-acting intravitreal anti-VEGF agents for neovascular age-related macular degeneration (nAMD).

This CME-accredited collection features:

• Expert panel discussions on emerging evidence and therapeutic strategies
• Real-world patient cases contextualizing clinical trial outcomes

Click on the activities below to explore valuable insights and clinical decision-making around:

• Therapy selection based on patient characteristics and disease progression
• Individualized dosing strategies and treatment intervals
• Monitoring response and adjusting therapy to reduce treatment burden